David L Lyon

US Patent:

6984403, Jan 10, 2006

Filed:

Jan 23, 2004

Appl. No.:

10/763340

Inventors:

Timothy A. Hagen - East Lyme CT, US
Julian B. Lo - Old Lyme CT, US
Avinash G. Thombre - East Lyme CT, US
Scott M. Herbig - East Lyme CT, US
Leah Elizabeth Appel - Bend OR, US
Marshall David Crew - Bend OR, US
Dwayne Thomas Friesen - Bend OR, US
David Keith Lyon - Bend OR, US
Scott Baldwin McCray - Bend OR, US
James Blair West - Bend OR, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 9/14

US Classification:

424489, 424400, 424464, 424451

Abstract:

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

US Patent:

20060029677, Feb 9, 2006

Filed:

Aug 25, 2005

Appl. No.:

11/212433

Inventors:

Timothy Hagen - East Lyme CT, US
Julian Lo - Old Lyme CT, US
Avinash Thombre - East Lyme CT, US
Scott Herbig - East Lyme CT, US
Leah Appel - Bend OR, US
Marshall Crew - Bend OR, US
Dwayne Friesen - Bend OR, US
David Lyon - Bend OR, US
Scott McCray - Bend OR, US
James West - Bend OR, US

International Classification:

A61K 31/7052
A61K 9/14

US Classification:

424489000, 514028000

Abstract:

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

US Patent:

20060039988, Feb 23, 2006

Filed:

Oct 26, 2005

Appl. No.:

11/259839

Inventors:

Timothy Hagen - East Lyme CT, US
Julian Lo - Old Lyme CT, US
Avinash Thombre - East Lyme CT, US
Scott Herbig - East Lyme CT, US
Leah Appel - Bend OR, US
Marshall Crew - Bend OR, US
Dwayne Friesen - Bend OR, US
David Lyon - Bend OR, US
Scott McCray - Bend OR, US
James West - Bend OR, US

International Classification:

A61K 31/7052
A61K 9/14

US Classification:

424489000, 514028000

Abstract:

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

US Patent:

20070190129, Aug 16, 2007

Filed:

Aug 31, 2004

Appl. No.:

10/931143

Inventors:

Imran Ahmed - East Lyme CT, US
Leah Appel - Bend OR, US
Walter Babcock - Bend OR, US
Dwayne Friesen - Bend OR, US
Scott Herbig - East Lyme CT, US
David Lyon - Bend OR, US
Sheri Shamblin - North Stonington CT, US
Ravi Shanker - Groton CT, US
Daniel Smithey - Bend OR, US
Steven Sutton - Niantic CT, US
Avinash Thombre - East Lyme CT, US
Kenneth Waterman - Waterfod CT, US

International Classification:

A61K 9/48
A61K 31/4965

US Classification:

424451000, 514255050

Abstract:

A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

US Patent:

20080015343, Jan 17, 2008

Filed:

Jul 18, 2007

Appl. No.:

11/779489

Inventors:

Timothy Hagen - East Lyme CT, US
Julian Lo - Old Lyme CT, US
Avinash Thombre - East Lyme CT, US
Scott Herbig - East Lyme CT, US
Leah Appel - Bend OR, US
Marshall Crew - Bend OR, US
Dwayne Friesen - Bend OR, US
David Lyon - Bend OR, US
Scott McCray - Bend OR, US
James West - Miramar FL, US

International Classification:

C07H 17/08

US Classification:

536007100

Abstract:

The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

US Patent:

20080199527, Aug 21, 2008

Filed:

Dec 9, 2005

Appl. No.:

11/722364

Inventors:

William J. Curatolo - Niantic CT, US
Scott M. Herbig - East Lyme CT, US
Steven R. LeMott - East Lyme CT, US
Julian B. Lo - Old Lyme CT, US
Leah E. Appel - Bend OR, US
Dwayne T. Friesen - Bend OR, US
David K. Lyon - Bend OR, US
Scott B. McCray - Bend OR, US
James B. West - Miramar FL, US

Assignee:

Pfizer Inc. - Groton CT

International Classification:

A61K 9/14
A61K 31/7048

US Classification:

424494, 424489, 514 29, 424497, 424498, 424499

Abstract:

A pharmaceutical composition is disclosed which comprises multiparticulates wherein said multiparticulates further comprise an azithromycin core and an enteric coating disposed upon said azithromycin core.

US Patent:

20100003331, Jan 7, 2010

Filed:

Sep 3, 2009

Appl. No.:

12/261678

Inventors:

Imran Ahmed - East Lyme CT, US
Leah Elizabeth Appel - Bend OR, US
Walter Christian Babcock - Bend OR, US
Dwayne Thomas Friesen - Bend OR, US
Scott Herbig - East Lyme CT, US
David Keith Lyon - Bend OR, US
Sheri L. Shamblin - North Stonington CT, US
Ravi Mysore Shanker - Groton CT, US
Daniel Tod Smithey - Bend OR, US
Steven C. Sutton - Niantic CT, US
Avinash Govind Thombre - East Lyme CT, US
Kenneth C. Waterman - Waterford CT, US
Jaymin C. Shah - Waterford CT, US
Parag Suresh Shah - Groton CT, US
Peter Wisniecki - Coventry CT, US
Dawn Renee Wagner - Groton CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 9/14
A61K 31/501

US Classification:

424489, 51425402, 977906

Abstract:

A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

US Patent:

20110002989, Jan 6, 2011

Filed:

Mar 4, 2009

Appl. No.:

12/920400

Inventors:

William John Curatolo - Niantic CT, US
Scott Max Herbig - East Lyme CT, US
Avinash Govind Thombre - East Lyme CT, US
Jaymin Chandrakant Shah - Waterford CT, US
Sheri L. Shamblin - North Stonington CT, US
Timothy Lukas - Kent, GB
William Brett Caldwell - Bend OR, US
Dwayne Thomas Friesen - Bend OR, US
David Keith Lyon - Bend OR, US
Christopher Donovan Craig - Bend OR, US

International Classification:

A61K 31/496
A61P 25/00
A61K 31/724
A61K 31/717
A61K 9/22

US Classification:

424468, 51425404, 514 58, 514 25, 977773

Abstract:

The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.